Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0YP7L
|
|||
| Former ID |
DNC003585
|
|||
| Drug Name |
SB-269970
|
|||
| Synonyms |
Pyrrolidine, 1-((3-hydroxyphenyl)sulfonyl)-2-(2-(4-methyl-1-piperidinyl)ethyl)-, (R)-; 201038-74-6; SB 269970; (R)-3-((2-(2-(4-Methylpiperidin-1-yl)ethyl)pyrrolidin-1-yl)sulfonyl)phenol; CHEMBL282199; SB269970; 3-[(2R)-2-[2-(4-methylpiperidin-1-yl)ethyl]pyrrolidin-1-yl]sulfonylphenol; SB-269,970; NCGC00025229-01; Tocris-1612; [3H]SB269970; AC1O7H0E; Lopac0_001059; SCHEMBL375474; GTPL3247; GTPL3233; CHEBI:92426; BCPP000080; ZINC3982174; BDBM50098551; 2921AH; AKOS024465019; CS-1645; CCG-205136; SB19510
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Sleep-wake disorder [ICD-11: 7A00-7B2Z; ICD-10: G47] | Terminated | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H28N2O3S
|
|||
| Canonical SMILES |
CC1CCN(CC1)CCC2CCCN2S(=O)(=O)C3=CC=CC(=C3)O
|
|||
| InChI |
1S/C18H28N2O3S/c1-15-7-11-19(12-8-15)13-9-16-4-3-10-20(16)24(22,23)18-6-2-5-17(21)14-18/h2,5-6,14-16,21H,3-4,7-13H2,1H3/t16-/m1/s1
|
|||
| InChIKey |
HWKROQUZSKPIKQ-MRXNPFEDSA-N
|
|||
| CAS Number |
CAS 201038-74-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
11114150, 11646537, 14827849, 14852068, 43224626, 47944892, 50104910, 77543877, 90340608, 103197548, 103995564, 114638177, 124750207, 134221723, 134340790, 135261782, 136367793, 137955553, 142785885, 172919549, 178100289, 178100296, 210275223, 210280862, 223394130, 223556755, 223702874, 226707028, 241383851, 242176196, 246475623, 249615589, 249855013, 250225791, 251971167, 252074169, 252212987, 252434592, 252474530
|
|||
| ChEBI ID |
CHEBI:92426
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 7 receptor (HTR7) | Target Info | Modulator | [3], [4] |
| KEGG Pathway | Ras signaling pathway | |||
| Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Serotonergic synapse | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Pathwhiz Pathway | Excitatory Neural Signalling Through 5-HTR 7 and Serotonin | |||
| Reactome | Serotonin receptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | |||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3233). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017732) | |||
| REF 3 | [(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol. 2000 May;130(2):409-17. | |||
| REF 4 | Characterization of SB-269970-A, a selective 5-HT(7) receptor antagonist. Br J Pharmacol. 2000 Jun;130(3):539-48. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.